{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:05:32Z","timestamp":1792598732807,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.113976","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T16:43:02Z","timestamp":1709311382000},"page":"113976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Anti-PD-(L)1 plus BRAF\/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma"],"prefix":"10.1016","volume":"202","author":[{"given":"Lea Jessica","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"V\u00e1raljai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Malte","family":"Placke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Krefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2024.113976_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.113976_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.113976_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113976_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2024.113976_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.113976_bib6","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2024.113976_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ejca.2024.113976_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004226","article-title":"Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)","volume":"10","author":"Tawbi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2024.113976_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"issue":"279","key":"10.1016\/j.ejca.2024.113976_bib10","doi-asserted-by":"crossref","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.ejca.2024.113976_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1052212","article-title":"Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma","volume":"5","author":"Homet Moreno","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2024.113976_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","article-title":"Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.","volume":"158","author":"Zimmer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2024.113976_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.113976_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10240","key":"10.1016\/j.ejca.2024.113976_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ejca.2024.113976_bib16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized Phase III trial evaluating spartalizumab plus dabrafenib and trametinib for braf v600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113976_bib17","unstructured":"FDA Approves Genentech\u2019s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma [news release]. [press release]. South San Francisco, CA, Approved July 30, 2020 Published July 30, 2020."},{"key":"10.1016\/j.ejca.2024.113976_bib18","unstructured":"Kombinationstherapie von Roche mit Tecentriq plus Cotellic und Zelboraf erh\u00e4lt Zulassung in der Schweiz zur Anwendung bei bestimmten Formen von fortgeschrittenem Melanom [press release]. 16 october 2020 2020."},{"issue":"1","key":"10.1016\/j.ejca.2024.113976_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2024.113976_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.18.01100","article-title":"RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis","volume":"37","author":"Liti\u00e8re","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.113976_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced braf-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113976_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.22.00221","article-title":"Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination","volume":"41","author":"Arance","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2024.113976_bib23","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.113976_bib24","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2021.39.15_suppl.9520","article-title":"Phase II study of triplet combination nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 na\u00efve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases","volume":"39","author":"Burton","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113976_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.02.023","article-title":"MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG","volume":"167","author":"Kreft","year":"2022","journal-title":"Eur J Cancer"},{"issue":"76","key":"10.1016\/j.ejca.2024.113976_bib26","doi-asserted-by":"crossref","first-page":"34336","DOI":"10.18632\/oncotarget.26149","article-title":"The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study","volume":"9","author":"Tietze","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2024.113976_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.12.007","article-title":"Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study","volume":"91","author":"Valpione","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.113976_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113976_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2021.01.034","article-title":"Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition","volume":"148","author":"Knispel","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2024.113976_bib30","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:09:25Z","timestamp":1727410165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"alternative-id":["S0959804924001321"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113976","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-(L)1 plus BRAF\/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113976"}}